FRI0614 Frequency of organ manifestations in chronic sarcoidosis

Background Chronic sarcoidosis is a systemic disease of unknown etiology, characterized by the histological finding of granulomas in involved organ systems. The most often affected organ is the lung with approximately 90–95%. Systematic data of organ manifestations other than the lung are scarce and show a wide range from 1–2% up to 50% depending on the series. Methods We analyzed data of newly diagnosed chronic sarcoidosis in 3 tertiary hospitals. We analyzed data on organ manifestations (OM), type of OM and laboratory findings. The certainty of OM was classified as grade 0 (not investigated), grade 1 (no sign of OM), grade 2 (clinical sign of OM), grade 3 (signs of OM in laboratory findings or imaging) and grade 4 (histological proven OM), respectively. Results We included 151 patients with biopsy-proven chronic sarcoidosis. Mean age was 50.8±15 years with a male predominance (87 [57.2%] vs. 65 [42.8%] patients). Except for 3 patients, all demonstrated pulmonary involvement. The predominant type of lung involvement was type I (mediastinal lymph node enlargement) in 54.2% and type II (mediastinal lymph node enlargement and interstitial involvement) in 27.7%. 96.5% of patients were investigated for an affection of the kidneys, 97.3% for hepatic, 92.7% for skin involvement, 68.8% for ocular manifestations, 67.5% for ear, nose, throat (ENT) manifestations and 92% for cardiac manifestations, respectively. Grade 3 (imaging/laboratory) and grade 4 (histology) findings were seen in the kidneys in 7.6/22.8%, in the liver in 13.3/11.9%, in the heart in 10.6/0.7%, in the eyes in 6.6/ Conclusions OM in chronic sarcoidosis are more frequent than suggested in the current literature, especially renal and hepatic. About 20% of patients with chronic sarcoidosis suffered from moderate to severe CKD due to sarcoidosis, which is a major organ complication contributing to overall morbidity. We recommend a systematic screening for OM in all patients with chronic sarcoidosis as it is performed in other systemic rheumatic disease. Disclosure of Interest None declared